Oskar Hansson performs internationally recognized clinical and translational research focusing on the early phases of Alzheimer's and Parkinson’s diseases. His work on biomarkers has led to over 400 original peer-reviewed publications. He heads the prospective and longitudinal Swedish BioFINDER studies, where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders.